Interstitial lung disease (ILD) is a debilitating and life-limiting condition, requiring multi-disciplinary care. While guidelines recommend early specialist palliative care referral to improve symptoms and quality of life, few patients access such care towards the end-of-life. This study aimed to explore clinicians’ perspectives regarding specialist palliative care and opioids to understand barriers to optimal care and guide clinical practice improvement initiatives.
Methods:
A cross-sectional, exploratory, qualitative study was undertaken with Australian respiratory clinicians caring for people with ILD (n = 17). In-depth, semi-structured interviews were audio-recorded, transcribed verbatim and coded. Thematic analysis was undertaken to extrapolate recurring ideas from the data.
Results:
Four themes were identified: 1) understanding how to improve patient care and support, 2) the need to dispel stigmatized beliefs and misconceptions, 3) the importance of trusted relationships and good communication and 4) the challenges of navigating the health-care system. Participants discussed the need to implement early specialist palliative care and symptom palliation to alleviate symptoms, provide emotional support and augment quality of life. Participants described challenges accessing palliative care and opioids due to stigmatized beliefs amongst patients and clinicians and difficulties navigating the health-care system. Trusted therapeutic relationships with patients and strong inter-disciplinary partnerships with collaborative education and communication were perceived to improve patients’ access to symptom palliation.
Conclusion:
Specialist palliative care and opioids were believed to improve patients’ quality of life, however, many barriers can make accessing such care challenging. To address these issues, multi-disciplinary collaboration, high-quality communication and trusted therapeutic relationships are crucial throughout the ILD illness journey.
Global Burden of Disease 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544.
2.
KimHJPerlmanDTomicR. Natural history of idiopathic pulmonary fibrosis. Respir Med. 2015;109(6):661–670.
3.
CottinVHiraniNAHotchkinDL, et al.Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076.
4.
OlsonALGiffordAHInaseNFernández PérezERSudaT. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018;27(150):180077.
5.
HutchinsonJFogartyAHubbardRMcKeeverT. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795–806.
6.
DoveEPOlsonALGlassbergMK. Trends in idiopathic pulmonary fibrosis-related mortality in the United States: 2000-2017. Am J Respir Crit Care Med. 2019;200(7):929–931.
7.
RaghuGRicheldiL. Current approaches to the management of idiopathic pulmonary fibrosis. Respir Med. 2017;129:24–30.
8.
AkhtarAAAliMASmithRP. Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis. 2013;10(3):127–133.
9.
RyersonCJBerkeleyJCarrieri-KohlmanVLPantilatSZLandefeldCSCollardHR. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011;139(3):609–616.
10.
Van ManenMJGGeelhoedJJMTakNCWijsenbeekMS. Optimizing quality of life in patients with idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2017;11(3):157–169.
11.
YountSEBeaumontJLChenSY, et al.Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung. 2016;194(2):227–234.
12.
RaghuGCollardHREganJJ, et al.An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
13.
SmallwoodNMannJGuoHGohN. Patients with fibrotic interstitial lung disease receive supportive and palliative care just prior to death. Am J Hosp Palliat Care. 2021;38(2):154–160.
14.
AhmadiZWyshamNGLundströmSJansonCCurrowDCEkströmM. End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. Thorax. 2016;71(6):510–516.
15.
KreuterMBendstrupERussellAM, et al.Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5(12):968–980.
16.
LankenPNTerryPBDelisserHM, et al.An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177(8):912–927.
17.
RajalaKLehtoJTSaarinenMSutinenESaartoTMyllarniemiM. End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliat Care. 2016;15(1):85.
18.
SharpCLambHJordanN, et al.Development of tools to facilitate palliative and supportive care referral for patients with idiopathic pulmonary fibrosis. BMJ Support Palliat Care. 2018;8(3):340–346.
19.
LindellKOLiangZHoffmanLA, et al.Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest. 2015;147(2):423–429.
20.
BajwahSHigginsonIJRossJR, et al.Specialist palliative care is more than drugs: a retrospective study of ILD patients. Lung. 2012;190(2):215–220.
21.
TurnpennyBShepherdKBorrillZ. M28|Respiratory clinicians’ experiences of end-of-life care in idiopathic pulmonary fibrosis [abstract]. Thorax. 2015;70:A239.
22.
BajwahSHigginsonIJRossJR, et al.The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. Palliat Med. 2013;27(9):869–876.
23.
BajwahSKoffmanJHigginsonIJ, et al.‘I wish I knew more…’ the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals. BMJ Support Palliat Care. 2013;3(1):84–90.
24.
Mc VeighCReidJLarkinPPorterSHudsonP.The experience of palliative care service provision for people with non-malignant respiratory disease and their family carers: an all-Ireland qualitative study. J Adv Nurs. 2018;74(2):383–394.
25.
AkiyamaNFujisawaTMoritaT, et al.Palliative care for idiopathic pulmonary fibrosis patients: pulmonary physicians’ view. J Pain Symptom Manage. 2020;60(5):933–940.
26.
AbernethyAPCurrowDCFrithPFazekasBSMcHughABuiC. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523–528.
27.
MatsudaYMaedaITachibanaK, et al.Low-dose morphine for dyspnea in terminally ill patients with idiopathic interstitial pneumonias. J Palliat Med. 2017;20(8):879–883.
28.
BarnesHMcDonaldJSmallwoodNManserR. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016;3(3):CD011008.
29.
CurrowDCKochovskaSFerreiraDJohnsonM. Morphine for the symptomatic reduction of chronic breathlessness: the case for controlled release. Curr Opin Support Palliat Care. 2020;14(3):177–181.
30.
VerberktCAvan den Beuken-van EverdingenMHJScholsJMGAHameleersNWoutersEFMJanssenDJA. Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial. JAMA Intern Med. 2020;180(10):1306–1314.
31.
JohnsonMJCurrowDC. Opioids for breathlessness: a narrative review. BMJ Support Palliat Care. 2020;10(3):287–295.
32.
MatsunumaRTakatoHTakedaY, et al.Patients with end-stage interstitial lung disease may have more problems with dyspnea than end-stage lung cancer patients. Indian J Palliat Care. 2016;22(3):282–287.
33.
ChenXTreanorDLeBSmallwoodN. Gaps in opioid prescription for severe breathlessness in hospitalised patients with chronic obstructive pulmonary disease or interstitial lung disease. J Pain Symptom Manage. 2020;60(3): e36–e39.
34.
FerreiraDHLouwSMcCloudP, et al.Controlled-release oxycodone vs. placebo in the treatment of chronic breathlessness—a multisite randomized placebo controlled trial. J Pain Symptom Manage. 2020;59(3):581–589.
35.
BraunVClarkeV. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.
36.
GreenJWillisKHughesE, et al.Generating best evidence from qualitative research: the role of data analysis. Aust N Z J Public Health. 2007;31(6):545–550.
37.
TongASainsburyPCraigJ. Consolidated Criteria for Reporting Qualitative Research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357.
38.
WalshSLF. Multidisciplinary evaluation of interstitial lung diseases: current insights. Eur Respir Rev. 2017;26(144):170002.
39.
JeongSOUhSTParkSKimHS. Effects of patient satisfaction and confidence on the success of treatment of combined rheumatic disease and interstitial lung disease in a multidisciplinary outpatient clinic. Int J Rheum Dis. 2018;21(8):1600–1608.
40.
KalluriMClaveriaFAinsleyEHaggagMArmijo-OlivoSRichman-EisenstatJ. Beyond idiopathic pulmonary fibrosis diagnosis: multidisciplinary care with an early integrated palliative approach is associated with a decrease in acute care utilization and hospital deaths. J Pain Symptom Manage. 2018;55(2):420–426.
41.
BarrattSLMoralesMSpeirsT, et al.Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs. BMJ Open Respir Res. 2018;5(1):e000360.
42.
MoorCCHeukelsPKoolMWijsenbeekMS. Integrating patient perspectives into personalized medicine in idiopathic pulmonary fibrosis. Front Med (Lausanne). 2017;4:226.
43.
Di PaoloASarkozyFRyllBSiebertU. Personalized medicine in Europe: not yet personal enough?BMC Health Serv Res. 2017;17(1):289.
44.
OvergaardDKaldanGMarsaaKNielsenTLShakerSBEgerodI. The lived experience with idiopathic pulmonary fibrosis: a qualitative study. Eur Respir J. 2016;47(5):1472–1480.
45.
SampsonCGillBHHarrisonNKNelsonAByrneA. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulm Med. 2015;15:155.
46.
BajwahSRossJRWellsAU, et al.Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention. Thorax. 2015;70(9):830–839.
